Ontology highlight
ABSTRACT:
SUBMITTER: Sawalha Y
PROVIDER: S-EPMC7293382 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Sawalha Yazeed Y Maddocks Kami K
OncoTargets and therapy 20200608
<h4>Abstract</h4>Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgki ...[more]